GSK receives European approval for Duodart®

The first fixed dose combination medicine for benign prostatic hyperplasia Issued: London UK GlaxoSmithKline (GSK) today announced that…

Continue Reading GSK receives European approval for Duodart®

GSK regulatory update – Avodart (dutasteride)

Issued: London UK, Philadelphia, US GlaxoSmithKline (GSK) announced today that it has re-submitted the supplemental New Drug Application (sNDA) for…

Continue Reading GSK regulatory update – Avodart (dutasteride)

GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

Issued: London UK GlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs since…

Continue Reading GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

GSK announces succession plan for leadership of Consumer Healthcare business

Emma Walmsley appointed President, Consumer Healthcare Europe and President Designate, Worldwide Consumer Healthcare Issued: London UK…

Continue Reading GSK announces succession plan for leadership of Consumer Healthcare business

GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine)

Issued: London UK GlaxoSmithKline (GSK) today confirmed that it has notified regulatory authorities of the presence of material from a…

Continue Reading GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine)

GlaxoSmithKline announces Swiss approval of Duodart®

The first fixed dose combination medicine for benign prostatic hyperplasia Issued: London UK GlaxoSmithKline (GSK) announced today that…

Continue Reading GlaxoSmithKline announces Swiss approval of Duodart®

GlaxoSmithKline commences Relovair Phase III asthma programme

Issued: London UK GlaxoSmithKline (GSK) announced today that the first asthma patient has commenced treatment with Relovair™ (fluticasone furoate/vilanterol trifenatate)…

Continue Reading GlaxoSmithKline commences Relovair Phase III asthma programme

GSK publishes 2009 Corporate Responsibility Report

Issued: Tuesday 16 March 2010, London UK In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment…

Continue Reading GSK publishes 2009 Corporate Responsibility Report

GlaxoSmithKline receives marketing authorisation in the EU for Revolade® (eltrombopag)

Issued: London UK GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted marketing authorisation for Revolade ® (eltrombopag)…

Continue Reading GlaxoSmithKline receives marketing authorisation in the EU for Revolade® (eltrombopag)

GSK commences succession plan for management of vaccines business

Issued: London UK, LSE announcement GlaxoSmithKline (GSK) today announced management changes related to its Vaccines business as part of a…

Continue Reading GSK commences succession plan for management of vaccines business

GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia

Issued: Research Triangle Park, London, UK Today, GlaxoSmithKline (GSK) responded to the recently released Senate Committee on Finance’s January 2010…

Continue Reading GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia

GSK statement on FDA’s proposed label revisions for some asthma medicines

Issued: Thursday, 18 February 2010, Research Triangle Park, NC GlaxoSmithKline is reviewing label changes proposed today by the US Food…

Continue Reading GSK statement on FDA’s proposed label revisions for some asthma medicines

GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS

Issued: Wednesday, 17 February 2010, London, UK, Research Triangle Park, NC & Santa Clara, CA —GlaxoSmithKline (NYSE: GSK) and XenoPort,…

Continue Reading GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS

GSK launches new specialist unit to research and develop medicines for rare diseases

Issued: Thursday 4 February 2010, London UK GSK today announces the formation of a new standalone unit specialising in the…

Continue Reading GSK launches new specialist unit to research and develop medicines for rare diseases

GSK announces appointment of Philippe Fauchet as President of GSK Japan

Issued: Thursday 4 February 2010, London UK GSK today announces the appointment of Philippe Fauchet as President of GSK Japan….

Continue Reading GSK announces appointment of Philippe Fauchet as President of GSK Japan

Results announcement for the fourth quarter 2009

See the quarterly results page for more information Source link

Continue Reading Results announcement for the fourth quarter 2009